leflunomide has been researched along with Cytomegalic Inclusion Disease in 32 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Data concerning the use of leflunomide-a drug approved for rheumatoid arthritis with in vitro anticytomegalovirus (CMV) activity-in lung transplant (LT) recipients are scarce." | 8.98 | Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: A case series and review of the literature. ( Aguado, JM; Alonso-Moralejo, R; Brañas, P; de Pablo-Gafas, A; Fernández-Ruiz, M; Folgueira, MD; Lopez-Medrano, F; Pérez-González, V; San-Juan, R; Silva, JT, 2018) |
| "The primary objective of this case series was to determine the clinical and virological responses of utilizing leflunomide as therapy for refractory cytomegalovirus infections, unresponsive to first-line therapy in allogeneic stem cell transplant patients." | 7.91 | Leflunomide therapy for refractory cytomegalovirus infections in hematopoietic stem cell transplant recipients. ( Doan, VP; Ferguson, JB; Jan, AS; Wang, E; Yeh, JC, 2019) |
| " We describe a case of a cytomegalovirus (CMV)-seronegative kidney transplant recipient from a CMV-seropositive donor, whose course was complicated during valganciclovir prophylaxis by CMV disease, ultimately progressing to ganciclovir, foscarnet, and cidofovir resistance." | 7.85 | Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report. ( Agrawal, N; Beltran, D; Echenique, IA; Najafian, N; Ramirez-Ruiz, L, 2017) |
| "Leflunomide, a disease-modifying antirheumatic drug (DMARD), has shown effectiveness in many autoimmune disorders and can suppress cytomegalovirus (CMV) disease in humans." | 7.81 | Can leflunomide play a role in cytomegalovirus disease prophylaxis besides its antirheumatic effects? ( Hsieh, SC; Lu, CH; Tsai, JH; Wu, MZ; Yu, CL, 2015) |
| "The immunomodulatory drug leflunomide (LEF) is frequently used for treating human cytomegalovirus (HCMV), but its antiviral mechanism is still unclear." | 7.79 | Leflunomide inhibits the apoptosis of human embryonic lung fibroblasts infected by human cytomegalovirus. ( Hua-Song, Z; Qi, R; Xiao-Feng, Z, 2013) |
| "Leflunomide has been shown to have immunosuppressive activity in experimental allograft models together with antiviral activity inhibiting CMV both in vitro and in vivo." | 6.77 | Leflunomide for cytomegalovirus: bench to bedside. ( Chacko, B; John, GT, 2012) |
| "Leflunomide has been used to treat resistant CMV infections, however, data on efficacy, safety, and guidance for therapeutic drug level monitoring are lacking." | 5.43 | Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series. ( Ariza-Heredia, E; Chemaly, RF; Doan, V; El Chaer, F; Jan, A; Mori, N; Oliver, N; Shah, D; Tayar, J; Tverdek, F; Wang, E, 2016) |
| "Leflunomide was selected as a last resort to avoid the nephrotoxicity of cidofovir." | 5.34 | Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. ( Abdelhalim, A; Almyroudis, NG; Battiwalla, M; Becker, J; Elefante, A; McCarthy, A; McCarthy, PL; Paplham, P; Segal, BH; Smith, P, 2007) |
| "Data concerning the use of leflunomide-a drug approved for rheumatoid arthritis with in vitro anticytomegalovirus (CMV) activity-in lung transplant (LT) recipients are scarce." | 4.98 | Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: A case series and review of the literature. ( Aguado, JM; Alonso-Moralejo, R; Brañas, P; de Pablo-Gafas, A; Fernández-Ruiz, M; Folgueira, MD; Lopez-Medrano, F; Pérez-González, V; San-Juan, R; Silva, JT, 2018) |
| "The primary objective of this case series was to determine the clinical and virological responses of utilizing leflunomide as therapy for refractory cytomegalovirus infections, unresponsive to first-line therapy in allogeneic stem cell transplant patients." | 3.91 | Leflunomide therapy for refractory cytomegalovirus infections in hematopoietic stem cell transplant recipients. ( Doan, VP; Ferguson, JB; Jan, AS; Wang, E; Yeh, JC, 2019) |
| " We describe a case of a cytomegalovirus (CMV)-seronegative kidney transplant recipient from a CMV-seropositive donor, whose course was complicated during valganciclovir prophylaxis by CMV disease, ultimately progressing to ganciclovir, foscarnet, and cidofovir resistance." | 3.85 | Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report. ( Agrawal, N; Beltran, D; Echenique, IA; Najafian, N; Ramirez-Ruiz, L, 2017) |
| "Leflunomide, a disease-modifying antirheumatic drug (DMARD), has shown effectiveness in many autoimmune disorders and can suppress cytomegalovirus (CMV) disease in humans." | 3.81 | Can leflunomide play a role in cytomegalovirus disease prophylaxis besides its antirheumatic effects? ( Hsieh, SC; Lu, CH; Tsai, JH; Wu, MZ; Yu, CL, 2015) |
| "The immunomodulatory drug leflunomide (LEF) is frequently used for treating human cytomegalovirus (HCMV), but its antiviral mechanism is still unclear." | 3.79 | Leflunomide inhibits the apoptosis of human embryonic lung fibroblasts infected by human cytomegalovirus. ( Hua-Song, Z; Qi, R; Xiao-Feng, Z, 2013) |
| "We previously reported that the immunosuppressive malononitrileamides leflunomide and FK778 exert antiviral activity against cytomegalovirus (CMV)." | 3.73 | Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. ( Chong, AS; Knight, DA; Meister, GT; Shen, J; Waldman, WJ; Williams, JW; Zeng, H, 2006) |
| "Leflunomide has been shown to have immunosuppressive activity in experimental allograft models together with antiviral activity inhibiting CMV both in vitro and in vivo." | 2.77 | Leflunomide for cytomegalovirus: bench to bedside. ( Chacko, B; John, GT, 2012) |
| "Leflunomide treatment for CMV disease in renal transplant recipients is effective, simple, and economical." | 2.71 | A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients. ( Balakrishnan, N; Chandy, S; Chandy, SJ; Fleming, DH; Jacob, CK; John, GT; Kirubakaran, MG; Krishnamurthy, K; Manivannan, J; Peter, S, 2005) |
| "Leflunomide has been used to treat resistant CMV infections, however, data on efficacy, safety, and guidance for therapeutic drug level monitoring are lacking." | 1.43 | Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series. ( Ariza-Heredia, E; Chemaly, RF; Doan, V; El Chaer, F; Jan, A; Mori, N; Oliver, N; Shah, D; Tayar, J; Tverdek, F; Wang, E, 2016) |
| "Treatment with leflunomide is a reasonable option in ganciclovir-resistant infection in kidney transplant recipients, providing effective viral elimination and reconstitution of adaptive anti-CMV immunity without excess risk of graft rejection." | 1.40 | Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report. ( Chmura, A; Ciszek, M; Foroncewicz, B; Mucha, K; Pączek, L, 2014) |
| "Leflunomide was initiated after a median of three episodes of CMV viremia, with a mean peak viral load of 245,826 copies/mL." | 1.36 | Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. ( Avery, RK; Bolwell, B; Braun, W; Budev, M; Fatica, R; Krishnamurthi, V; Lard, M; Lurain, N; Mawhorter, SD; Mossad, SB; Poggio, E; Shrestha, R; Stephany, B; Waldman, WJ; Yen-Lieberman, B; Young, JB, 2010) |
| "Leflunomide was selected as a last resort to avoid the nephrotoxicity of cidofovir." | 1.34 | Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. ( Abdelhalim, A; Almyroudis, NG; Battiwalla, M; Becker, J; Elefante, A; McCarthy, A; McCarthy, PL; Paplham, P; Segal, BH; Smith, P, 2007) |
| "Leflunomide has excellent antiviral activity against cytomegalovirus (CMV) in animal models and is considerably less expensive than intravenous ganciclovir." | 1.32 | Leflunomide therapy for cytomegalovirus disease in renal allograft recepients. ( Chandy, S; Jacob, CK; John, GT; Manivannan, J; Peter, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.25) | 18.2507 |
| 2000's | 7 (21.88) | 29.6817 |
| 2010's | 22 (68.75) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Santhanakrishnan, K | 1 |
| Yonan, N | 1 |
| Iyer, K | 1 |
| Callan, P | 1 |
| Al-Aloul, M | 1 |
| Venkateswaran, R | 1 |
| Echenique, IA | 1 |
| Beltran, D | 1 |
| Ramirez-Ruiz, L | 1 |
| Najafian, N | 1 |
| Agrawal, N | 1 |
| Silva, JT | 1 |
| Pérez-González, V | 1 |
| Lopez-Medrano, F | 1 |
| Alonso-Moralejo, R | 1 |
| Fernández-Ruiz, M | 1 |
| San-Juan, R | 1 |
| Brañas, P | 1 |
| Folgueira, MD | 1 |
| Aguado, JM | 1 |
| de Pablo-Gafas, A | 1 |
| Wang, E | 2 |
| Jan, AS | 1 |
| Doan, VP | 1 |
| Ferguson, JB | 1 |
| Yeh, JC | 1 |
| Verkaik, NJ | 1 |
| Hoek, RA | 1 |
| van Bergeijk, H | 1 |
| van Hal, PT | 1 |
| Schipper, ME | 1 |
| Pas, SD | 1 |
| Beersma, MF | 1 |
| Boucher, CA | 1 |
| Jedema, I | 1 |
| Falkenburg, F | 1 |
| Hoogsteden, HC | 1 |
| van den Blink, B | 1 |
| Murk, JL | 1 |
| Ciszek, M | 1 |
| Mucha, K | 1 |
| Foroncewicz, B | 1 |
| Chmura, A | 1 |
| Pączek, L | 1 |
| Lu, CH | 1 |
| Tsai, JH | 1 |
| Wu, MZ | 1 |
| Yu, CL | 1 |
| Hsieh, SC | 1 |
| Kneidinger, N | 1 |
| Giessen, C | 1 |
| von Wulffen, W | 1 |
| Milger, K | 1 |
| Schramm, R | 1 |
| Jäger, G | 1 |
| Nitschko, H | 1 |
| Striebinger, H | 1 |
| Behr, J | 1 |
| Neurohr, C | 1 |
| Boeckh, M | 1 |
| Murphy, WJ | 1 |
| Peggs, KS | 1 |
| Miszewska-Szyszkowska, D | 1 |
| Mikołajczyk, N | 1 |
| Komuda-Leszek, E | 1 |
| Wieczorek-Godlewska, R | 1 |
| Świder, R | 1 |
| Dęborska-Materkowska, D | 1 |
| Szmidt, J | 1 |
| Durlik, M | 1 |
| Gagneux-Brunon, A | 1 |
| Pillet, S | 1 |
| Laurent, B | 1 |
| Mariat, C | 1 |
| Michalet, M | 1 |
| Lucht, F | 1 |
| Botelho-Nevers, E | 1 |
| Gómez Valbuena, I | 1 |
| Alioto, D | 1 |
| Serrano Garrote, O | 1 |
| Ferrari Piquero, JM | 1 |
| Ambrose, T | 1 |
| Sharkey, LM | 1 |
| Louis-Auguste, J | 1 |
| Rutter, CS | 1 |
| Duncan, S | 1 |
| English, S | 1 |
| Gkrania-Klotsas, E | 1 |
| Carmichael, A | 2 |
| Woodward, JM | 1 |
| Russell, N | 1 |
| Massey, D | 1 |
| Butler, A | 1 |
| Middleton, S | 1 |
| Morita, S | 1 |
| Shinoda, K | 1 |
| Tamaki, S | 1 |
| Kono, H | 1 |
| Asanuma, H | 1 |
| Nakagawa, K | 1 |
| Oya, M | 1 |
| El Chaer, F | 1 |
| Mori, N | 1 |
| Shah, D | 1 |
| Oliver, N | 1 |
| Jan, A | 1 |
| Doan, V | 1 |
| Tverdek, F | 1 |
| Tayar, J | 1 |
| Ariza-Heredia, E | 1 |
| Chemaly, RF | 1 |
| Bright, PD | 1 |
| Gompels, M | 1 |
| Donati, M | 1 |
| Johnston, S | 1 |
| Snydman, DR | 1 |
| Avery, RK | 3 |
| Mossad, SB | 3 |
| Poggio, E | 1 |
| Lard, M | 1 |
| Budev, M | 1 |
| Bolwell, B | 1 |
| Waldman, WJ | 5 |
| Braun, W | 1 |
| Mawhorter, SD | 1 |
| Fatica, R | 1 |
| Krishnamurthi, V | 1 |
| Young, JB | 1 |
| Shrestha, R | 1 |
| Stephany, B | 1 |
| Lurain, N | 2 |
| Yen-Lieberman, B | 2 |
| Teschner, S | 1 |
| Burst, V | 1 |
| Orden, AO | 1 |
| Chuluyan, JC | 1 |
| Colombini, AC | 1 |
| Barbera, RF | 1 |
| Chacko, B | 1 |
| John, GT | 4 |
| Goldsmith, PM | 1 |
| Husain, MM | 1 |
| Zhang, H | 1 |
| Middleton, SJ | 1 |
| Qi, R | 1 |
| Hua-Song, Z | 1 |
| Xiao-Feng, Z | 1 |
| Manivannan, J | 2 |
| Chandy, S | 2 |
| Peter, S | 2 |
| Jacob, CK | 2 |
| Bolwell, BJ | 1 |
| Longworth, DL | 1 |
| Taege, AJ | 1 |
| Kohn, D | 1 |
| Long, JR | 1 |
| Curtis, J | 1 |
| Kalaycio, M | 1 |
| Pohlman, B | 1 |
| Williams, JW | 4 |
| Fleming, DH | 1 |
| Chandy, SJ | 1 |
| Balakrishnan, N | 1 |
| Krishnamurthy, K | 1 |
| Kirubakaran, MG | 1 |
| Chong, AS | 3 |
| Zeng, H | 1 |
| Knight, DA | 3 |
| Shen, J | 2 |
| Meister, GT | 1 |
| Sudarsanam, TD | 1 |
| Sahni, RD | 1 |
| Battiwalla, M | 1 |
| Paplham, P | 1 |
| Almyroudis, NG | 1 |
| McCarthy, A | 1 |
| Abdelhalim, A | 1 |
| Elefante, A | 1 |
| Smith, P | 1 |
| Becker, J | 1 |
| McCarthy, PL | 1 |
| Segal, BH | 1 |
| Lurain, NS | 2 |
| Miller, DM | 2 |
| Sedmak, DD | 2 |
| Blinder, L | 1 |
8 reviews available for leflunomide and Cytomegalic Inclusion Disease
| Article | Year |
|---|---|
Management of ganciclovir resistance cytomegalovirus infection with CMV hyperimmune globulin and leflunomide in seven cardiothoracic transplant recipients and literature review.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Ganciclovir; | 2022 |
Experience with leflunomide as treatment and as secondary prophylaxis for cytomegalovirus infection in lung transplant recipients: A case series and review of the literature.
Topics: Adult; Aged; Cytomegalovirus; Cytomegalovirus Infections; Female; Follow-Up Studies; Humans; Immunos | 2018 |
Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Drug Therapy, | 2013 |
Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies.
Topics: Acetates; Adoptive Transfer; Animals; Antiviral Agents; Benzimidazoles; Cell- and Tissue-Based Thera | 2015 |
Successful low-dose leflunomide treatment for ganciclovir-resistant cytomegalovirus infection with high-level antigenemia in a kidney transplant: A case report and literature review.
Topics: Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Viral; Female; Ganciclovir; Humans; I | 2016 |
Successful oral treatment of Ganciclovir resistant cytomegalovirus with Maribavir in the context of primary immunodeficiency: First case report and review.
Topics: Administration, Oral; Antiviral Agents; Benzimidazoles; Blood; Cytomegalovirus; Cytomegalovirus Infe | 2017 |
Leflunomide: a drug with a potential beyond rheumatology.
Topics: Animals; Antirheumatic Agents; Biological Availability; Contraindications; Cytomegalovirus Infection | 2010 |
Leflunomide: a possible alternative for gangciclovir sensitive and resistant cytomegalovirus infections.
Topics: Animals; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infections; Drug Resistance, Vi | 2006 |
2 trials available for leflunomide and Cytomegalic Inclusion Disease
| Article | Year |
|---|---|
Leflunomide for cytomegalovirus: bench to bedside.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Humans; Isoxazoles; Leflunomide; Tran | 2012 |
A prospective evaluation of leflunomide therapy for cytomegalovirus disease in renal transplant recipients.
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Female; Humans; Isoxazoles; Kidney Transplantat | 2005 |
22 other studies available for leflunomide and Cytomegalic Inclusion Disease
| Article | Year |
|---|---|
Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report.
Topics: Aged; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Dose-Respo | 2017 |
Leflunomide therapy for refractory cytomegalovirus infections in hematopoietic stem cell transplant recipients.
Topics: Adult; Aged; Cytomegalovirus Infections; DNA-Directed DNA Polymerase; DNA, Viral; Female; Genotype; | 2019 |
Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report.
Topics: Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Viral; Ganciclovir; Graft Rejection; | 2014 |
Can leflunomide play a role in cytomegalovirus disease prophylaxis besides its antirheumatic effects?
Topics: Adult; Aged; Antirheumatic Agents; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Dr | 2015 |
Trip to immunity: resistant cytomegalovirus infection in a lung transplant recipient.
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Viral; Female; Foscarnet; Ganc | 2014 |
Severe cytomegalovirus infection in a second kidney transplant recipient treated with ganciclovir, leflunomide, and immunoglobulins, with complications including seizures, acute HCV infection, drug-induced pancytopenia, diabetes, cholangitis, and multi-or
Topics: Adult; Antiviral Agents; Cholangitis; Cytomegalovirus Infections; Diabetes Mellitus, Type 2; Fatal O | 2015 |
A case of BK virus nephropathy in a stem cell transplant recipient: a rare or under-recognized cause for Acute Kidney injury.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; BK Virus; Ciprofloxacin; Cord Blood Stem Cell Transplant | 2015 |
[Use of leflunomide in a cytomegalovirus infection resistant: a report of a case].
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Female; Human | 2016 |
Cytomegalovirus Infection and Rates of Antiviral Resistance Following Intestinal and Multivisceral Transplantation.
Topics: Adult; Aged; Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Viral; Female; Foscarnet | 2016 |
Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series.
Topics: Aged; Antiviral Agents; Chemotherapy, Adjuvant; Cytomegalovirus; Cytomegalovirus Infections; Drug Mo | 2016 |
Leflunomide: a small step forward in meeting the urgent need for treatment of drug-resistant cytomegalovirus infection.
Topics: Algorithms; Antiviral Agents; Benzimidazoles; Cytomegalovirus Infections; Drug Resistance, Viral; Ga | 2010 |
Utility of leflunomide in the treatment of complex cytomegalovirus syndromes.
Topics: Antiviral Agents; Cytomegalovirus Infections; Ganciclovir; Heart Transplantation; Humans; Immunosupp | 2010 |
Leflunomide use in a cytomegalovirus infection of a patient with dermatomyositis.
Topics: Antirheumatic Agents; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Dermatomyositis | 2012 |
Case report: Multidrug-resistant cytomegalovirus in a modified multivisceral transplant recipient.
Topics: Adult; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resi | 2012 |
Leflunomide inhibits the apoptosis of human embryonic lung fibroblasts infected by human cytomegalovirus.
Topics: Apoptosis; Cell Proliferation; Cell Shape; Cytomegalovirus; Cytomegalovirus Infections; Embryo, Mamm | 2013 |
Leflunomide therapy for cytomegalovirus disease in renal allograft recepients.
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Costs; Female; Humans; India; Isoxazoles; | 2004 |
Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection.
Topics: Bone Marrow Transplantation; Cytomegalovirus Infections; Drug Resistance, Viral; Drug Therapy, Combi | 2004 |
Concurrent antiviral and immunosuppressive activities of leflunomide in vivo.
Topics: Animals; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Graft Rejection; Heart; Hear | 2006 |
Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Therapy, Co | 2007 |
Second look at leflunomide "failure" to control cytomegalovirus infection in the setting of renal failure.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Humans; Isoxazoles; Leflunomide; Rena | 2007 |
Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide.
Topics: Antiviral Agents; Blotting, Northern; Cytomegalovirus; Cytomegalovirus Infections; DNA-Directed DNA | 1999 |
Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide.
Topics: Animals; Antiviral Agents; Cells, Cultured; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; | 1999 |